TY - JOUR
T1 - Ototoxicity in children receiving platinum chemotherapy
T2 - Underestimating a commonly occurring toxicity that may influence academic and social development
AU - Knight, Kristin R.Gilmer
AU - Kraemer, Dale F.
AU - Neuwelt, Edward A.
PY - 2005
Y1 - 2005
N2 - Purpose: To describe the frequency and severity of ototoxicity in a series of pediatric patients treated with platinum-based chemotherapy. Patients and Methods: Serial audiologic evaluations were conducted for 67 patients aged 8 months to 23 years who received platinum-based chemotherapy. Audiologic data was analyzed to determine time to hearing-loss using American Speech-Language- Hearing Association (ASHA) criteria, and the effects of treatment and patient characteristics on the incidence and severity of ototoxicity. Results: Bilateral decreases in hearing were seen in 61% of patients (median time to hearing loss, 135 days). Children treated for medulloblastoma, osteosarcoma, and neuroblastoma had greater incidence and severity of hearing loss. Agreement between the usually reported National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and ASHA criteria was inadequate. Conclusion: Traditional reporting of toxicity data (CTCAE) has under-reported ototoxicity and minimized the significance of hearing loss in children. As pediatric patients experience improved survival, the effects and implications of high-frequency hearing loss with regard to academic achievement and speech and language development are important considerations, especially in patients younger than 5 years.
AB - Purpose: To describe the frequency and severity of ototoxicity in a series of pediatric patients treated with platinum-based chemotherapy. Patients and Methods: Serial audiologic evaluations were conducted for 67 patients aged 8 months to 23 years who received platinum-based chemotherapy. Audiologic data was analyzed to determine time to hearing-loss using American Speech-Language- Hearing Association (ASHA) criteria, and the effects of treatment and patient characteristics on the incidence and severity of ototoxicity. Results: Bilateral decreases in hearing were seen in 61% of patients (median time to hearing loss, 135 days). Children treated for medulloblastoma, osteosarcoma, and neuroblastoma had greater incidence and severity of hearing loss. Agreement between the usually reported National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and ASHA criteria was inadequate. Conclusion: Traditional reporting of toxicity data (CTCAE) has under-reported ototoxicity and minimized the significance of hearing loss in children. As pediatric patients experience improved survival, the effects and implications of high-frequency hearing loss with regard to academic achievement and speech and language development are important considerations, especially in patients younger than 5 years.
UR - http://www.scopus.com/inward/record.url?scp=33644848462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644848462&partnerID=8YFLogxK
U2 - 10.1200/JCO.2004.00.5355
DO - 10.1200/JCO.2004.00.5355
M3 - Article
C2 - 16314621
AN - SCOPUS:33644848462
SN - 0732-183X
VL - 23
SP - 8588
EP - 8596
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 34
ER -